Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma

Published:2013-02-28 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Galaal Khadra¹,van der Heijden Esther²,Godfrey Keith³,Naik Raj³,Kucukmetin Ali³,Bryant Andrew⁴,Das Nagindra¹,Lopes Alberto D⁵

Affiliation:

1. Princess Alexandra Wing, Royal Cornwall Hospital; Gynaecological Oncology; Truro UK TR1 3LJ

2. Radboud University Nijmegen Medical Centre; Department of Gynaecology and Obstetrics; Nijmegen Netherlands

3. Northern Gynaecological Oncology Centre; Gynaecological Oncology; Queen Elizabeth Hospital Gateshead Tyne & Wear UK NE9 6SX

4. Newcastle University; Institute of Health & Society; Medical School New Build Richardson Road Newcastle upon Tyne UK NE2 4AX

5. University of Exeter Medical School; Exeter Devon UK

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD006812.pub3/fullpdf

Reference46 articles.

1. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study;Homesley;Journal of Clinical Oncology

2. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study;Sutton;Gynecologic Oncology,2000

3. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus;Wolfson;Gynecologic Oncology,2007

4. A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study;Asbury;American Journal of Clinical Oncology,1998

5. Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study;Currie;Gynecologic Oncology,1996

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma;Technology in Cancer Research & Treatment;2024-01

2. Cervical carcinosarcoma, report of some cases and a literature review;International Journal of Gynecology & Obstetrics;2023-10-30

3. Prognostic Importance of Lymph-Vascular Space Involvement in Stage I Endometrioid Type Endometrial Cancer;Bezmialem Science;2023-07-25

4. A personalized nomogram for predicting 3-year overall survival of patients with uterine carcinosarcoma in a care in Southern Thailand;OBSTET GYNECOL SCI;2023

5. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3